H2020Индивидуална стипендия2019–2021

I-AM-GUT · Impact of maternal Adrenomedullin on the Microbiome and Gut health: insights into preventing chronic intestinal disorders

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2019-11-01 → 2021-10-31
Финансиране от ЕС: 184 591 €
Участници: 1
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Майчинският хормон адреномедулин влияе върху развитието на бактериите в червата на бебето. Разбирането на този процес помага за откриване на нови маркери за диагностика и стратегии за предпазване от хронични възпалителни заболявания на червните пътища.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Impact of maternal Adrenomedullin on the Microbiome and Gut health: insights into preventing chronic intestinal disorders

The I-AM-GUT Project will investigate the role of maternal adrenomedullin (AM), a hormone naturally produced in the body, in bacterial colonisation of the gut in early-life, thus affecting gut development, health, and future susceptibility to suffer from intestinal disorders. This project also aims to test the efficacy of AM as a biomarker for inflammatory bowel disease (IBD). IBD is a chronic disease characterised by relapsing episodes of gastrointestinal inflammation. It has become a global disease with over 3 million patients only in Europe. The financial costs of the disease are, in general, high with an estimated €4.6-5.6 billion per year in Europe. However, these estimates do not factor the "real" price of IBD, which can impede career aspirations, instil social stigma and impair quality of life in patients (with 20-25% of European patients experiencing continuous symptoms, such as diarrhoea, rectal bleeding, abdominal pain, joint pain, weight loss, without permanent relief). Studies addressing IBD have increased exponentially in the last decades, but its causes and pathogenesis remains largely unkown, especially at the molecular level. These highlight the need for research aimed to predict the evolution of IBD and for the discovery of new biomarkers for diagnosis, which will result in the development of innovative prevention strategies and treatments to manage this complex disease. Several scientific studies have indicated that an adequate establishment of bacteria composition (i.e. microbiota) in our intestines during early life and its maintenance throughout childhood is crucial for developing a healthy gut and to reduce the risk of developing certain disease conditions later in life. As previously mentioned, AM is a hormone that is beneficial for the gut and is involved in the promotion of a healthy microbiota by being a potent killer agent of harmful bacteria and promoter of beneficial bacteria in the gut. AM is also detected at high concentrations in all body fluids and secretions, including the mammal's milk, but the role of AM found in the milk for intestinal health and disease is currently unknown.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Inflammatory Bowel Disease (IBD) is a chronic gastrointestinal inflammation that has become a global disease with a high economic burden. Adrenomedullin (AM), a hormone associated with gut microbiota and physiology, is naturally present at high concentrations in maternal milk and during lactation. Using a conditional model for AM the fellow identified a protective role of endogenous AM in IBD onset, however relatively little is known about its exact role in early-life, in colitis development or as a potential diagnostic tool for IBD. The fellow hypothesizes that maternal AM’s impact on the breast and gut microbiome may regulate gut and immune development and colitis susceptibility. By creating the first mammary gland conditional knock out for AM, she will uncover novel disease mechanisms and provide the basis for new diagnostic and prevention strategies for IBD. The final goals of this multi-disciplinary project are 1) to unravel the impact of AM on the breast microbiome, the maternal AM influence on healthy infant gut development and the prevention of colitis; 2) to reveal the impact that nutritional intervention and AM administration have on milk and gut microbiome to compensate for dysbiosis and in preventing colitis progression; 3) to evaluate the value of AM as an independent prognostic biomarker for IBD. The project has been carefully designed to match the fellow’s expertise in generating transgenic mice, AM biology and molecular techniques; the expertise of the host institution (APC Microbiome Ireland) in next generation sequencing, cell culture models (organoids), flow cytometry and human studies; and the expertise of the secondment supervisor (UCD) in in situ hybrisation and digital pathology technology. Plans to improve the fellow’s ability to disseminate research findings, gain transferable skills, and learn to manage a project are in place. Ultimately at the end of this fellowship, she will have advanced her position to become an independent researcher.

Оригинален текст от CORDIS (на английски).

Участници

UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK · CorkКоординаторИрландия